ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
Gilead's CAR-T cell therapy Yescarta gains EU clearance; meets first resistance from NICE
August 29, 2018Gilead Sciences' Kite unit announced that the European Commission approved Yescarta (axicabtagene ciloleucel) as a treatment for adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and primary mediastinal large B-cell lymphoma (PMBCL)
Pharma Sources Insight January 2025
